ONKURE THERAPEUTICS

OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solid tumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with ot... her targeted therapies. OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.

#SimilarOrganizations #People #Financial #Event #Website #More

ONKURE THERAPEUTICS

Social Links:

Industry:

Biotechnology Life Science Therapeutics

Founded:

2011-01-01

Address:

Boulder, Colorado, United States

Country:

United States

Website Url:

http://www.onkuretherapeutics.com

Total Employee:

Status:

Active

Contact:

720-307-2892

Email Addresses:

[email protected]

Total Funding:

67.49 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins

Similar Organizations

axcella-logo

Axcella

Axcella is a biotechnology company providing therapeutics development solutions.

demetrix-logo

Demetrix

Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.

enliven-therapeutics-logo

Enliven Therapeutics

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

immusoft-logo

Immusoft

Immusoft, a biotechnology company, commercializes technologies that program the human immune system by modifying the DNA in related cells.

numab-logo

Numab

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

tyra-biosciences-logo

Tyra Biosciences

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.

vigil-neuroscience-logo

Vigil Neuroscience

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.

Current Employees Featured

anthony-d-piscopio_image

Anthony D. Piscopio
Anthony D. Piscopio Co-Founder, President & CEO @ OnKure Therapeutics
Co-Founder, President & CEO
2011-04-01

gail-eckhardt_image

Gail Eckhardt
Gail Eckhardt Chief Medical Officer @ OnKure Therapeutics
Chief Medical Officer

xuedong-liu_image

Xuedong Liu
Xuedong Liu Chief Science Officer @ OnKure Therapeutics
Chief Science Officer

kevin-s-litwiler_image

Kevin S. Litwiler
Kevin S. Litwiler Senior Vice President of DMPK and Clinical Pharmacology @ OnKure Therapeutics
Senior Vice President of DMPK and Clinical Pharmacology
2022-06-01

jason-leverone_image

Jason Leverone
Jason Leverone CFO @ OnKure Therapeutics
CFO
2022-01-01

not_available_image

Keith Olivia
Keith Olivia Vice President of Corperate Affairs and Genarl Counsel @ OnKure Therapeutics
Vice President of Corperate Affairs and Genarl Counsel

jennifer-r-diamond_image

Jennifer R. Diamond
Jennifer R. Diamond Chief Medical Officer @ OnKure Therapeutics
Chief Medical Officer
2021-10-01

not_available_image

Donna Peak
Donna Peak Director @ OnKure Therapeutics
Director

mark-l-boys_image

Mark L. Boys
Mark L. Boys VP of Discovery Chemistry @ OnKure Therapeutics
VP of Discovery Chemistry
2021-09-01

Founder

anthony-d-piscopio_image

Anthony D. Piscopio

xuedong-liu_image

Xuedong Liu

Investors List

surveyor-capital_image

Key Employee Changes

Date	New article
2022-06-21	OnKure Therapeutics Appoints Kevin S. Litwiler, Ph.D., as Senior Vice President of DMPK and Clinical Pharmacology
2022-02-08	OnKure Therapeutics Appoints Jason Leverone, CPA, as Chief Financial Officer
2021-11-09	OnKure Therapeutics Appoints Mark L. Boys, Ph.D., as Vice President of Discovery Chemistry
2021-10-14	OnKure Therapeutics Appoints Jennifer R. Diamond, M.D., as Chief Medical Officer

Official Site Inspections

http://www.onkuretherapeutics.com Semrush global rank: 4.37 M Semrush visits lastest month: 2.58 K

Host Informations
Whois Informations

Loading ...